Previous 10 | Next 10 |
Alnylam Pharmaceuticals, Inc (ALNY) Q3 2020 Earnings Conference Call November 05, 2020 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Andy Orth - Senior Vice President...
Alnylam Pharmaceuticals (ALNY): Q3 Non-GAAP EPS of -$1.58 misses by $0.24; GAAP EPS of -$2.18 misses by $0.54.Revenue of $125.85M (+79.6% Y/Y) beats by $6.8M.Press Release For further details see: Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue
− Achieved Third Quarter 2020 ONPATTRO ® Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Product Worldwide – − Achieved Third Quarter 2020 GIVLAARI ® G...
Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$1.34 (+10.7% Y/Y) and the consensus Revenue Estimate is $119.05M (+69.9% Y/Y).Analyst expects R&D of $161.4M.Over the last 2 yea...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: 29 th Annual Credit Suisse Virtual Healthcare Conference on Monday, Novemb...
− Award Recognizes the Nobel-Prize Winning Science Behind ONPATTRO and its Impact on Patients Living with the Polyneuropathy of Hereditary ATTR (hATTR) Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named the company a top employer in its annual survey of the biotech and pharmaceutical industry. “We are thri...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2020 on Thursday, November 5, 2020, before the U.S. financial markets open. Management will provi...
Following up on its announcement in late September, Alnylam Pharmaceuticals ([[ALNY]] -0.1%) reports detailed positive results from its Phase 3 clinical trial, ILLUMINATE-B, evaluating RNAi therapeutic lumasiran in adults and children with primary hyperoxaluria type 1 (PH1), a disorder caused...
– Lumasiran Demonstrated a 72 Percent Mean Reduction in Urinary Oxalate and Improvements in Nephrocalcinosis in ILLUMINATE-B Phase 3 Study in Children Under the Age of Six and as Young as Three Months – – Alnylam Also Presents New Results from ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...